Kailera Therapeutics priced a $625 million IPO, positioning the obesity-focused developer among the largest biotech offerings in the past several years. The company said it will use proceeds to fund its obesity pipeline and to support medicines licensed from China’s Hengrui Pharma. The launch arrives amid renewed investor appetite for late-stage metabolic biology, but also reflects the broader funding shift toward pipeline quality and commercial-readiness signals. For the sector, a large upsized obesity IPO functions as a valuation reference point for other metabolic and GLP-adjacent companies considering public-market access. Kailera’s move is likely to influence near-term IPO underwriting and investor expectations for obesity assets, especially those backed by international licensing deals.